NCT01663389View on ClinicalTrials.gov

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 10, 2012

Primary Completion Date

October 5, 2012

Study Completion Date

October 5, 2012

Conditions
Infections, Bacterial
Interventions
DRUG

GSK1322322 1000 mg containing radioactive 14C-GSK1322322

GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.

DRUG

GSK1322322 1200 mg containing radioactive 14C-GSK1322322

GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01663389 - A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose | Biotech Hunter | Biotech Hunter